Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Suspected CSF Shunt Obstruction
Interventions: ShuntCheck-Micro-Pumper (SCMP), Imaging; Device
Lead sponsor: NeuroDx Development; Industry
Eligibility: 35 Months to 29 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 11
States / cities: Wilmington, Delaware • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Major Depressive Disorder
Interventions: Escitalopram; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Algorithm Verification
Interventions: There is no intervention; Other
Lead sponsor: Intelomed, Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: McMurray, Pennsylvania

Conditions: Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
Interventions: Efavirenz, Quizartinib; Drug
Lead sponsor: Daiichi Sankyo Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cerebral Stroke
Interventions: Anklebot (Ankle Robot); Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Renal Cell Carcinoma
Interventions: 150-Water, 62Cu-ethylglyoxal bis, Positron Emission Tomography, Sunitinib; Drug · Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions: AU-011, Suprachoroidal Microinjector, PDT Laser; Drug · Device
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Recurrent Platinum Resistant Ovarian Cancer
Interventions: cediranib and olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 25
States / cities: Mobile, Alabama • Anchorage, Alaska • Downey, California + 21 more

Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Interventions: docetaxel, placebo, gefitinib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intermittent Claudication
Interventions: Cilostazol; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Surgery, Neuromuscular Blockade
Interventions: TetraGraph; Device
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Month and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Volunteers, Anemia, Sickle Cell
Interventions: AG-946, AG-946 Matched Placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: La Jolla, California • Boston, Massachusetts • New York, New York + 4 more

Conditions: Healthy
Interventions: tasimelteon, Rifampin, Ketoconazole; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Stroke, Spinal Cord Injuries and Disorders, Hemiparesis After Stroke
Interventions: Spinal Cord Stimulator (Medtronic Inceptiv™ System), Physical Therapy; Device · Other
Lead sponsor: Marco Capogrosso; Other
Eligibility: 22 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pediatric Pulmonary Hypertension
Interventions: Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Months to 18 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Aurora, Colorado • St. Petersburg, Florida • Baltimore, Maryland + 7 more

Conditions: CD55-deficient Protein-losing Enteropathy, CHAPLE
Interventions: Pozelimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Year and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rhytides, Wrinkle
Interventions: Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3), PRP Only, Placebo; Device · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 30 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Interstitial Lung Disease, Obstructive Sleep Apnea
Interventions: Continuous positive airway pressure (CPAP) therapy, Nox A1 Recorder; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 2,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Nonsmall Cell Lung Cancer, Performance Status
Interventions: Pembrolizumab, Atezolizumab, Cemiplimab-Rwlc, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed, Cisplatin, Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13), QLQ-C30 Global Health/Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes, PROMIS and FACT-G Questionnaires, Sleep Disorder Assessments (ISI, Berlin Sleep Questionnaire); Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Stroke, Parkinson Disease, Multiple Sclerosis, Oropharyngeal Dysphagia, Alzheimer Disease, Dementia
Interventions: Dysphagia Detection System; Device
Lead sponsor: Société des Produits Nestlé (SPN); Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Downey, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Interventions: BGJ398 (infigratinib); Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more

Conditions: Degenerative Lumbar Spondylolisthesis
Interventions: Use of OP-1 Putty in Uninstrumented posterolateral fusion; Device
Lead sponsor: Olympus Biotech Corporation; Industry
Eligibility: 18 Years to 81 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 5
States / cities: New Haven, Connecticut • Chicago, Illinois • Royal Oak, Michigan + 2 more

Conditions: Acute Ischemic Stroke
Interventions: High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS), Sham tDCS; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Los Angeles, California • Baltimore, Maryland • Durham, North Carolina

Conditions: Iron Deficiency Anemia
Interventions: Ferric carboxymaltose; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Miami Springs, Florida

Search by objective public record fields.

ShuntCheck-Micro-Pumper Pediatric Clinical Outcomes Study

Brain GABA Levels and Treatment Response in Major Depressive Disorder

mCVI Pilot Study: Algorithm Verification

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

Cortical and Biomechanical Dynamics of Ankle Robotics Training in Stroke

PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions

TetraGraph to Evaluate Onset and Recovery Times of Rocuronium

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Spinal Cord Stimulation Combined With Physical Therapy in Post-Stroke Upper-Limb Motor Hemiparesis

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

BCT-HA Kit for Dehydrated and Wrinkled Skin

Assessment of Continuous Positive Airway Pressure Therapy in OSA and ILD

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Videofluoroscopic Swallowing Study (VFSS)

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

A Prospective Pilot Study of the OP-1 Putty in Uninstrumented Posterolateral Fusions

Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044